With thousands of press releases published each month, it can be difficult to keep up with everything on . To help healthcare ...

Here is a list of matters listed at NSW Local and Environment Court on Friday. Today's court listings are published as part ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

AbbVie’s Option-to-License Deal With Neomorph AbbVie announced an option-to-license agreement with Neomorph to develop novel molecular glue degraders for multiple targets across oncology and ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN and partner Daiichi’s novel TROP2 ...

Plus, news about Madrona and Ab­dera: Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics … ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.